• 1
    Blijham G, Wagener T, Wils J, de Greve J, Buset M, Bleiberg H, Lacave A, Dalmark M, Selleslag J, Collette L, Sahmoud T. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 1996; 14: 226673.
  • 2
    O'Connell MJ, Klaassen DJ, Everson LK, Cullinan S, Wieand HS. Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic. NCI Monogr 1987; 1858.
  • 3
    Focan C, Kreutz F, Focan-Henrard D, Moeneclaey N. Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. Eur J Cancer 2000; 36: 3417.
  • 4
    Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11: 90913.
  • 5
    Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 14138.
  • 6
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000; 343: 90514.
  • 7
    Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 38017.
  • 8
    Modi S. Seidman AD. An update on epidermal growth factor receptor inhibitors. Curr Oncol Rep 2002; 4: 4755.
  • 9
    Saijo N, Tamura T, Nishio K. Problems in the development of target-based drugs. Cancer Chemother Pharmacol 2000; 46: S435.
  • 10
    Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001; 37: S1622.
  • 11
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S915.
  • 12
    Speer G, Cseh K, Winkler G, Takacs I, Barna I, Nagy Z, Lakatos P. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. Eur J Cancer 2001; 37: 14638.
  • 13
    Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001; 5: 5666.
  • 14
    Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 655065.
  • 15
    Woodburn JR, Morris CQ, Kelly H. EGF receptor tyrosine kinase inhibitors as anti-cancer agents-preclinical and early clinical profile of ZD1839. Cell Mol Biol Lett 1998; 3: 3489.
  • 16
    Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa™ (ZD1839) in a EGFR-expressing multidrug resistant cell line in vitro and in vivo. Int J Cancer 2002; 98: 3105.
  • 17
    Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 90916.
  • 18
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco A.R, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 205363.
  • 19
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 488592.
  • 20
    Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001; 28: 6779.
  • 21
    Kusaba H, Tamura T, Nakagawa K, Yamamoto N, Kudoh S, Negoro S, Takeda K, Tanigawara Y, Fukuoka M. A phase I intermittent dose-escalation trial of ZD1839 (‘IRESSA’) in Japanese patients with solid malignant tumors. Clin Cancer Res 2000; 6: abs381.
  • 22
    Kris M, Ranson M, Ferry D, Hammond L, Averbuch S, Ochs J, Rowinsky E. Phase I study of oral ZD1839(‘IRESSA’): A novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI)—Evidence of good tolerability and activity. Clin Cancer Res 1999; 5: abs 99
  • 23
    Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 2001; 7: 2029.
  • 24
    Ohmori T, Ao Y, Nishio K, Saijo N, Arteaga CL, Kuroki T. Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; ‘Iressa’) in vivo. Proc Am Assoc Cancer Res 2000; 41: abs 3072.
  • 25
    Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G. Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86: 81927.
  • 26
    Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29: 3746.
  • 27
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 488592.
  • 28
    Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86: 115761.
  • 29
    Goldshmit Y, Erlich S, Pinkas-Kramarski R. Neuregulin rescues PC12-ErbB4 cells from cell death induced by H2O2. Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 4637985.
  • 30
    Meves A, Stock SN, Beyerle A, Pittelkow MR, Peus D. H2O2 mediates oxidative stress-induced epidermal growth factor receptor phosphorylation. Toxicol Lett 2001; 122: 20514.
  • 31
    Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura S, Shinomura Y, Matsuzawa Y. Epidermal growth factor receptor mediates stress-induced expression of its ligands in rat gastric epithelial cells. Gastroenterology 2001; 120: 10816.
  • 32
    Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 2000; 275: 1462431.
  • 33
    Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 2002; 21: 872331.
  • 34
    Kitagawa D, Tanemura S, Ohata S, Shimizu N, Seo J, Nishitai G, Watanabe T, Nakagawa K, Kishimoto H, Wada T, Tezuka T, Yamamoto T, et al. Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation: its implication in an anti-apoptotic function. J Biol Chem 2002; 277: 36671.